On February 1, local time, Gilead Science's official website announced its 2021 results, with a total annual revenue of $27.305 billion, an increase of 11% year-on-year. R&D investment was US$5.363 billion, an increase of 6.4% year-on-year. Remdesivir sales revenue increased 98% to $5.56 billion in 2021.
In terms of business performance in various disease areas, HIV sales revenue of $16.3 billion, down -4%; HCV sales revenue of only nearly $1.9 billion for the whole year, continued to show a downward trend; HBV and HDV business increased by 13% in 2021 to achieve revenue of $969 million. Cell therapy sales revenue continued to grow rapidly and steadily, achieving $871 million in revenue, up 43 percent.
Screenshot of Gilead's official website.
HIV drugs, represented by Bitolvir and Lenacapavir, are the core pillars of Gilead. The new 3-in-1 HIV drug, Pitovy, is a core pillar of Gilead's growth, with sales revenue of $8.624 billion in 2021, up 19% year-over-year.
In 2021, Gilead's oncology business also achieved revenue of more than $1 billion, becoming a new growth area for the company, while the cell therapy field is Gilead's strategic highland in the field of oncology. Aguilensay's 2021 sales were $690 million, up 23 percent from last year, and Tecartus also achieved sales of $170 million in its first full fiscal year.
In 2021, Aguilensay became the first CAR-T cell therapy for indolent lymphoma and reporting 5-year survival data for refractory large B-cell lymphoma and showing long-term survival benefits, while being approved for marketing in China.
Screenshot of Gilead's earnings report.
In 2022, Gilead will once again usher in important milestones for key products, including Trodelvy, Aguilensay and Lenacapavir, which is expected to continue to expand its product advantages, the report said.
Editor-in-charge: Qiu Yue